Dr. Matthew J. Ehrhardt
Claim this profileSt. Jude Children's Research Hospital
Studies Cancer
Studies Hodgkin's Lymphoma
2 reported clinical trials
17 drugs studied
Area of expertise
1Cancer
Stage II
Stage I
Stage III
2Hodgkin's Lymphoma
Stage II
Stage I
Stage III
Affiliated Hospitals
Clinical Trials Matthew J. Ehrhardt is currently running
Chemotherapy + Radiotherapy
for Hodgkin's Lymphoma
This is a phase II study using risk and response-adapted therapy for low, intermediate and high risk classical Hodgkin lymphoma. Chemotherapy regimens will be based on risk group assignment. Low-risk and intermediate- risk patients will be treated with bendamustine, etoposide, Adriamycin® (doxorubicin), bleomycin, Oncovin® (vincristine), vinblastine, and prednisone (BEABOVP) chemotherapy. High-risk patients will receive Adcetris® (brentuximab vedotin), etoposide, prednisone and Adriamycin® (doxorubicin) (AEPA) and cyclophosphamide, Adcetris® (brentuximab vedotin), prednisone and Dacarbazine® (DTIC) (CAPDac) chemotherapy. Residual node radiotherapy will be given at the end of all chemotherapy only to involved nodes that do not have an adequate response (AR) after 2 cycles of therapy for all risk groups.
Recruiting1 award Phase 216 criteria
Nivolumab + Chemo-Immunotherapy
for Large B-Cell Lymphoma
This phase III trial compares the effects of nivolumab with chemo-immunotherapy versus chemo-immunotherapy alone in treating patients with newly diagnosed primary mediastinal B-cell lymphoma (PMBCL). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Treatment for PMBCL involves chemotherapy combined with an immunotherapy called rituximab. Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving nivolumab with chemo-immunotherapy may help treat patients with PMBCL.
Recruiting2 awards Phase 321 criteria
More about Matthew J. Ehrhardt
Clinical Trial Related6 years of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Matthew J. Ehrhardt has experience with
- Cyclophosphamide
- Bendamustine
- Bleomycin
- Brentuximab Vedotin
- Doxorubicin
- DTIC
Breakdown of trials Matthew J. Ehrhardt has run
Cancer
Hodgkin's Lymphoma
B-Cell Lymphoma
Large B-Cell Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Matthew J. Ehrhardt specialize in?
Matthew J. Ehrhardt focuses on Cancer and Hodgkin's Lymphoma. In particular, much of their work with Cancer has involved Stage II patients, or patients who are Stage I.
Is Matthew J. Ehrhardt currently recruiting for clinical trials?
Yes, Matthew J. Ehrhardt is currently recruiting for 2 clinical trials in Memphis Tennessee. If you're interested in participating, you should apply.
Are there any treatments that Matthew J. Ehrhardt has studied deeply?
Yes, Matthew J. Ehrhardt has studied treatments such as Cyclophosphamide, Bendamustine, Bleomycin.
What is the best way to schedule an appointment with Matthew J. Ehrhardt?
Apply for one of the trials that Matthew J. Ehrhardt is conducting.
What is the office address of Matthew J. Ehrhardt?
The office of Matthew J. Ehrhardt is located at: St. Jude Children's Research Hospital, Memphis, Tennessee 38105 United States. This is the address for their practice at the St. Jude Children's Research Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.